T he second-generation antipsychotic clozapine has consistently been shown to be the most effectiveantipsychotic in treatment-resistant schizophrenia in controlled trials!,2 meta-analysis? and longtermeffectiveness studies."
In addition to its superior efficacy in treatment-resistant schizophrenia, clozapine offers clinical advantages overother antipsychotics. These includea low risk of extrapyramidal symptoms' (reflected in itsapproval in mostcountries for use in peopleintolerant of other antipsychotics, particularly tardive dyskinesia); reduction of suicide in schizophrenia' (approved for this indication in the US); andreduction in the frequency andduration of hospital admissions.v Thisresearch evidence has led currentclinical practice guidelines to recommendthat clozapinebe considered at the earliest opportunity for people with treatment-resistant schizophrenia. This is defined as a lackof satisfactory clinical response to trials (withrecommended treatment duration 6-8 wk) of at least 2 antipsychotics (at least1 of which should be a non-c1ozapine second-generation antipsychotic such as risperidone, olanzapine, or quetiapine)!o.u However, clozapine is associated with other problematic effects suchas sedation, hypersalivation, weight gain,constipation, insulin resistance, and diabe~s, 13, 14 and, more rarely, risks of cardiac adverse events suchas myocarditis andcardiomy-Author information provided at the endof the text.
OBJECTIve: Todescribe the treatment pathway and patterns of clozaplne use In patients with schizophrenia, Including coprescribed psychotropic medications, and compare the extent of coprescribing of clozapino with that of non-clozaplne schizophrenia treatment In community mental health services In the Auckland and Northland regions of New Zealand.
METHODS: A retrospective chart review was conducted for adult outpati ents receiving care from community mental healthserviceson October 31 , 2004 . Data collected for all patients prescribed an antipsychotic Included demographics (sex, age, ethnlcity); principal diagnosis (Diagnostic and Statistical Manual of Mental Disorders, 4th edition); comorbld conditions; duralionof mentallllness; psychiatric admissions; and treatment information (psychotropic medications, with doseand route of administration). If clozapine had been started aller the introduction of full government prescriptionsubsidy (February 1999), additional data, including year of Initiation and prior antipsychotic history, were collected. Analysis included all outpatients witha diagnosis of schizophrenia (including schlzoaffective disorder). RESULTS: Antipsychotics were prescribed for 2796schizophreniapatients; 32.8% were prescribed clozaplne, with a mean dose of 372 mg/day and an average durationof illness of 9.7 years before starting clozaplne. Patients who had started treatment after clozaplne was funded by the government (59.3%) had receiveda median of 3 antipsychotic drugs priorto starting c/ozapine; mostof the treatment regimens Included 1 second-generation antipsychotic (91 .2%). Clozaplne patientswere less likely to be coprescribed another antipsycholic compared with non-c/ozaplne pati ents (11.7% vs 17.6%; P< 0.001). Both the clozapine andnonclozapine groups had a low total number of psychotropic medications prescribed (median 2); for clozapine patients, the second drug was most likely to be for treatmentof hypersalivalion.
opathy. !5,16 It is the significant hematologic risks (severe neutropenia and agranulocytosis) that havenecessitated the need forregular bloodtesting and registration witha national monitoring database in most countries that use clozapine." In New Zealand, weekly white blood cell counts are required forthe first 18weeks of therapy, followed by monthly testing thereafter.!7,18 Guidance for regularmonitoring of metabolic andcardiac adverse eventsfor all antipsychotic medications has also been outlined by the New Zealand Mental Health Metabolic Working GroupInitiative,"
Estimates of the number of people with treatment-resistant schizophrenia who are expectedto benefitfrom clozapine range from 25% to 50%. Previousresearch indicated that clozapine is underused.P-" Similarly, other research suggested that treatment is delayedfor longerthan is desirable to improve clinical, social, and functional outcomes; that is, clozapine is not prescribed as soon as 2 other antipsychotics have failed." Factors affecting the use of clozapine may include issues relating to patient consent, patient adherence to monitoring, adverse effects, the increasing availability of other second-generation antipsychotics,21,23,24 and cost of this medication.
Although clozapine was registered for use in New Zealandin early 1993,funding was restricted to the discretionary use of a hospital's budget intended for inpatient treatment only.Difficulties for patients in gainingaccess to clozapine treatment were highlighted in the mid-1990s 25 and, in February 1999, clozapine became a fully funded medicinefor all patients in the communityor hospital setting. National underprescribing of clozapine continued to be reported." and steps were taken to monitor its use regionally. At that time, nationaldata extracts of dispensing data from electronic pharmacy databases did not provide informationabout the number of individuals taking a particularmedication or about the individual's diagnosis. This study was therefore set up with the aim of using clinical audit and feedback" as a tool to compare everyday best practice with recommended practice for adults engaged with a communitymental health center (CMHC) in Auckland (the largest city in New Zealand) and Northland (a mixed urban and rural regionnorthof Auckland).
This paper reports first on the treatment pathway and pattern of clozapineprescribing in schizophrenia, and second on the extent to which other psychotropic drugs were coprescribed with clozapine. The coprescription of psychotropic drugswith clozapine in patients with schizophrenia is comparedwith schizophrenia patientsprescribedalternative antipsychotic treatment.
Methods

STUDY SAMPLE
This cross-sectional retrospective studyincludedall outpatients (aged 15-64 y) attending a CMHC in the Auck-land and Northland regions on October 31, 2004, The CMHCs are locatedoutsidethe hospital setting,spread geographicallyacross these regions, and managed by 4 District Health Boards (DHBs; DHB-A, -B, -C, and -D). The catchment area's population aged 15-64 yearswas 872,718 people, based on Census 2001 data,28.3! Only outpatients with a diagnosis of schizophrenia (including schizoaffective disorder) who were prescribed an antipsychotic were included in this analysis (N = 2796).32
DATA COLLECTION
Studydata were extracted by a trainedseniorpsychiatric research nursefrom the paperand/orelectronic clinical me used at each CMHC and fromeach DHB's patient informationmanagement system. Data wereentered by a clerical assistant into a custom-designed Microsoft Access database with predetermined responseoptionsto ensuredata quality and facilitate analysis. Datacollected included demographics (sex, age, ethnicity), principal diagnosis,comorbid conditions, duration of mental illness (time, in years, from first contact with a treatment provider until2004),psychiatric admission history, and treatment data(psychotropic medication, withtotaldailydoseand routeof administration). The principal Axis I diagnosis(Diagnostic and Statistical Manualof Mental Disorders, 4th ed. 32) documentedat the psychiatric assessment closestto October31, 2004,was recorded as the major mental disorder (these assessments are usually con-ductedevery3 months to coincide withprescription requirements),Axis I and II comorbidities were recordedif documented at the psychiatric assessment closestto the studyreviewpoint. Documented physical health comorbidities were recorded, as well as medications prescribed concurrently (database allowed recording of 2 additional Axis1,2 AxisIl, and up to 8 Axis ill comorbidities). Other information was extractedfrom clinicalsummaries,case reviews,discharge summaries, and the multidisciplinary progress notes recorded for the 3 monthson either side of the reviewpoint. Psychiatric admission history was verified withthe National Health Events database maintained by the National Health Informa-tionService.
All psychotropic data (including antipsychotics, antidepressants, mood stabilizers, sedative-hypnotics, and drugs used for managementof neurologic adverse effects of antipsychotics) were recordedfrom the medication chart and verified in the body of the clinical notes or with duplicate copies of the prescription wherever possible. For patients prescribed clozapine,the year of initiation was also recorded. When clozapine initiationwas from 1999 onward (the year community funding became available), information aboutthe typeand numberof antipsychotics prescribed prior to clozapine was collected. The number of antipsychotic treatments was defined as the number of differentantipsychotics prescribed regularly at a therapeutic antipsychotic wwwsheannalscom TheAnnals ofPharmacotherapy • 2008June, Volume 42 • 853 dosefor a minimum of 6 weeks. If the drug was usedmore thanonce,it wascounted as a single antipsychotic treatment. Where there was a clearly documented break in clozapine treatment (> 12 wk, and alternative antipsychotic treatment wasprescribed), theclozapine restart datewasrecorded. The national clozapine registration database was used to verify the treatment start/restart date(s) and discontinuation date and reason for discontinuation where relevant. For the purposes of comparison,antipsychotic doses were converted intochlorpromazine equivalents (CPZe). The methodology usedfor thisis described elsewhere,"
The study was approved by the Auckland Regional Ethics Committee (AKL2000/065).
DATA ANALYSIS
Data analyses were conducted using SPSS version 15 (SPSS,Chicago, IL).Continuous variables werecompared between groups using independent t-tests or analysis of variance.Discrete variables were analyzed using ' 1; tests.
When sample distributions did not satisfy assumptions of normality (eg, age, durationof illness,psychiatric admissions), nonparametric tests were used (Mann-Whitney U or Kruskal-Wallis) or the variable was log transformed for analysis (eg, antipsychotic dose). Logisticregression was used to investigate variables associated with 2 outcome measures: pre-clozapine treatment duration (year of first contact with a treatment provider to year clozapine started) and antipsychotic coprescription with clozapine. To minimizethe type I errorassociated withmultiple comparisons, the threshold required to demonstrate statistical significance was set at p less than0.D1
Results
There were 2796 outpatients with schizophrenia or schizoaffective disorderbeing treatedwith an antipsychotic in the 4 mentalhealth services in October2004. Within this group, 917 (32.8%) were prescribed clozapine. The clozapinegroup had a mean age of 37.1 years; more than two-thirds were male, half were identified as European, and, on average, they had been unwell for 15years.
Comparisons betweenthe clozapine and non-clozapine treatmentgroups are shown in Table 1 . There were more females in the non-clozapine group. The ethnicity profile also differed, with fewer European and Asian and more Maori and Pacific people treated with clozapine.Patients prescribed clozapine had been unwellfor longerand were less likely to have comorbidmentaldisorder(s), primarily seen with lowerrates of movement disorders diagnosed as Axis I neuroleptic-induced disorders (Table 1) .There was no significant difference between groups in the proportion with a comorbid Axis II disorder. Physical comorbidity was grouped (0, 1,2-4, and~conditions) for analysis.
Again,there was no significant difference between groups, although patients treated with clozapine were found to have higherratesof gastrointestinal conditions.
The average dailydose of clozapine was 372 mg (median 350, SO 152, range 50-900). Average daily doses did not vary significantly across the 4 DHBs (clozapinedose log transformed F 3 ,913 =0.77;p =0.29).
PATHWAY TO CLOZAPINE TREATMENT
Almostthe entire clozapine group(99.6%) had data that allowed calculation of the duration between year of first contact with a treatmentprovider and the clozapinestarting year. Thirty-seven percenthad started clozapine within 5 years of first contact with a provider (18.3% in :$2 y, 18.6% in 3-5 y), 24.8% within 6-10 years, and 38.3% morethan 10years afterfirstcontact. The mean pre-clozapine treatmentduration was 9.7 years (median8; SO 7.8; range0-43). Longerpre-clozapine treatment duration was found in older patients (aged~50 y, mean 20.4 y; aged 30-49 y, 10.1 y; aged 15-29 y, 3.2 y; p < 0.001). It was also longer in European patients (mean 11.3 y; Maori, 8.7 y; Pacific,7.8 y; Asian, 6.7 y; p < 0.001), and for patients who started clozapine treatment before it was funded in 1999 (mean 10.5 vs. 9.2 y; p < 0.001). There was no significantdifference in the pre-clozapine treatment duration between sexes(p =0.285)or DHBs (p =0.107).
Full government prescription subsidy for clozapine started in February 1999;59.3% (n = 544) started clozapine after this date. A history of antipsychotic treatment was available for 533 of these patients (98.0%). Figure 1 shows the distribution of patients by the numberof antipsychotic treatments prior to starting clozapine. The average numberof antipsychotics prescribed was 3.5 (median 3.0, SO 1.7,range 1-10).The majority had beentreated with an oral second-generation antipsychotic (91.2%), 61.9%were prescribed at least one oralfirst-generation antipsychotic, and 46.7% were prescribed a depot antipsychotic before the switchto clozapine. Only 39 patients had beentreatedwith all 3 oral second-generation antipsychotics available in New Zealand at the time of the audit (risperidone, olanzapine, quetiapine) before starting clozapine.
COPRESCRIBED MEDICATION
Antipsychotic
Of the clozapine group, 107(11.7%) were concurrently prescribed at least one other antipsychotic ( Table 2 ).1\vo patients wereregularly coprescribed 2 antipsychotics in addition to clozapine. Twenty-seven of thoseprescribed combinations were with first-generation antipsychotics, 5 of which were depot antipsychotics. Clozapine was coprescribed with anothersecond-generation antipsychotic in 82 patients. The average augmentation doses of the copre-scribed antipsychotics are shown in Table 2 ; these data indicate that most were prescribed at doses below those regarded as therapeutic antipsychotic doses (300-600 mg/day CPZe).
The rates of antipsychotic polytherapy varied across the 4 health services, with a trend for higher rates in DHB-D patients (21.6% vs DHB-A, 7.3%; DHB-B, 13.2%; DHB-C, 13.6%; P = 0.011). There was also some evidence to support differences based on pre-clozapine treatment duration, although these differences did not reach statistical significance (duration >10 y, 14.2% polytherapy; durationỹ , 85% polytherapy; p = 0.058). Combination antipsychotic prescription was not associated with sex (p = 0.559), ethnicity (p = 0.856), or age group (p = 0.139). When rates of antipsychotic poly therapy were compared, there was a reduced likelihood of coprescription of another antipsychotic in the clozapine versus non-clozapine group (l1.7% vs 17.6%;X2165;df= l;p<O.oOl).
Clozapine Prescribing/or Schizophrenia in New Zealand
Other Coprescrlbed Medication
Overall, the clozapine group was prescribed an average of 1.83 psychotropic medications including the antipsychotic (SD 0.95; median 2; range 1-6). Comparison with the non-clozapine group showed no significant difference (mean 1.93; SD 1.07; median 2; range 1-7) (Mann-Whitney Up = 0.125). Table 3 shows the other psychotropics coprescribed with clozapine. When rates of coprescription of other psychotropics were compared with the non-clozapine treatment group, there was an increased likelihood of being prescribed a medication to manage adverse effects with clozapine (25.1%) versus non-clozapine treatment (19.0%) (X 213.95; df= 1; p < 0.001). This difference is predominantly due to the use ofterazosin (an urantagonist), which is prescribed specifically for clozapine-induced hypersalivation." Overall, there was no significant difference in rates of anticholinergics prescribed between the clozapine risks are seenwithbothfirst-and second-generation antipsychotictreatments.S"Finally, ratesof gastrointestinal comorbiditywere higherwith clozapine treatment. Constipation is a commonproblem (_14%)14 and is likely due to the drug's potentantimuscarinic activity. Othergastrointestinal adverse effects reported with clozapine include heartburn, nausea! vomiting, and reduced gut motility.'v"
The average clozapine dose prescribed in this study (372 mg/day) was within the recommended therapeutic dose range,17.18 comparable to that shown in Australian outpatient surveys,41,4Z and consistentwith clinicaltrial data," but lower than doses reported in outpatient studies from the US. 44 On average, it took almost 10 years from first contact with a health provider to starting clozapine treatment. Patients who had a longerdelay in treatment were more likely to be older, of European ethnicity, and to have started clozapine when funding was restricted (1993) (1994) (1995) (1996) (1997) (1998) . Almost two-thirds of the patients were started on clozapine after government funding was initiated. On average, they had been prescribed 3 different antipsychotics prior to starting clozapine; for most patients, this included at least one second-generationantipsychotic (91%). The funding change appears to have been associated with a positiveincrease in the number of outpatients able to access clozapine for treatment-resistant schizophrenia.
Reassuringly, most outpatients were not sequentially given trialsof every second-generation antipsychotic available in New Zealand before being started on clozapine; rather, only 7% had a treatment history that included all 3 second-generationantipsychotics.This contrasts with reports from the US and China, where clozapineuse has decreased as the market share increased with non-clozapine second-generation antipsychotics. z1 ,13,24 The duration before clozapine was initiated appears to be significantly delayed.This is concerningin light of evidence-based guidelines recommending early use, the UK long-termeffectiveness study CUtLASS 2 (Cost Utilityof the Latest Antipsychotic Drugs in Schizophrenia Study),' and emergingresearch supporting early clozapine treatment in first-episode patients." The CUtLASS study showed that to achievea good response at one year in patients who had alreadyfailed 2 antipsychotic trials,it was better to commence clozapine than to switch to another second-generation antipsychotic.' In a recently published US study of first-episode patients who had failed to respond to 2 antipsychotics, introducing clozapine (as early as 25 wk into start of treatment) resulted in a better response than switching. The authors suggested that clozapine use should be consideredwithinthe first 6 months of schizophrenia treatment and that it should 
Discussion
This retrospective study found that 32.8%of outpatients diagnosed with schizophreniaor schizoaffectivedisorder were prescribed clozapine; this is consistent with the expectedrate of treatment resistance.
The clozapine-treated group had experienced longer illness duration but overall was not experiencing greater mentalor physical health morbidity than was the comparison non-clozapine-treated group. There are 3 findings of particular note.The first of these fmdings is the lower rates of comorbid neuroleptic-induced movement disorders associated with clozapine treatment. This is consistent with lower rates of extrapyramidal symptoms reported with clozapine, especially when comparedwith the first-generation antipsychotics and risperidone.P'f"Second, while it is well documented thatclozapine is associated withdisorders such as obesity, diabetes, hypertension, and hyperlipidemia," therealso are reports of significant excessmortality and morbidity from cardiovascular disease in schizophrenia patients versus the general popuiation.J6.39In this studysimilar ratesof cardiac andendocrine comorbidity werefoundin both the clozapine and non-clozapine groups (-8% and -10%, respectively). This reflects age-matched cohortstudies, whichhave reported that increased risks may not solely be.due to the direct effect of antipsychotics and that these and non-clozapine groups (18.4% vs 17.0%,respectively; X Z 0.822; df = 1;P= 0.364).The rate of coprescribed sedative-hypnotic treatment was, however,significantly lower for the clozapine compared with the non-clozapine group (10.7% vs 16.7%;X Z 17.84;df = 1; p < 0.001). Although there was no difference in termsof ratesof coprescribed antidepressants (clozapine, 17.4% vs non-clozapine 16.6%; X Z 0.35; df = 1; P = 0.556), there was a trend toward lower rates of mood stabilizer coprescription in the clozapine group (13.7% vs non-clozapine, 16.7%; X Z 4.12; df =1; P= 0.042).
be repositioned as a second-rather than third-line treatment. 4S The issue of earlier use of clozapine was also examined by Kerwin." He reviewed arguments for and againstearlier clozapine use than its current license allows and concludedthat it shouldbe used soonerrather than later and after a single unsuccessful trial of one second-generationantipsychotic.
In a small review of 112 schizophrenia inpatientsin the UK, clozapine treatment was foundto be delayed an average of up to 5 years," Fiveyearsis shorter than the New Zealand average of 10 years; however, comparing the 2 studies is not possible because of differences in the calculation of treatment Clozapine Prescribing for Schiwphrenio in New Zealand delay. Treatment delay in the UK studywas calculated from the sixth week of treatment with a second antipsychoticto firstuse of clozapine and excluded the time beforeclozapine was available in the UK (pre-1990) . If this definition had been appliedto the New Zealand data, it would have shortened the calculation, but the degree to which it would have changed the overall resultis unknown. However, in linewith the findings of this study, the UK studyalso foundthat older patients andthosediagnosed beforethe introduction of clozapinehad a longerdelayin starting clozapine. Antipsychotic coprescription with clozapine in this study was found to be low (-12%). Patients with longer durationbefore clozapinewas initiated were more likely to be coprescribed another antipsychotic, suggesting the existence of a group with a longer history of poor response who were potentiallymore treatmentresistant. When rates of antipsychotic coprescription with clozapine were compared with the rates in the non-clozapine group, they were found to be lower (12% and 18%,respectively).
Reported rates of antipsychotic coprescribing with clozapine vary. The cross-sectional rate in this study is comparable to that shown in a Chinese outpatient survey" (13%) and lower than rates reported in the US (22% at inpatient discharge," 36.2% polytherapy for >60 days," 21.0% for polytherapy >90 days").
There is little evidence to support antipsychotic combinations, but in severe treatment-resistant schizophrenia there are mixed reports supporting clozapineaugmentation with another antipsychotic, in particular sulpiride'" (not available in New Zealand) and risperidone.v" Outside of this situation,antipsychotic polytherapy is typically recommended for only brief periods of switching, acute relapse,12~or perhaps for treatment-resistant schizophrenia when clozapine is contraindicated or when a patient refuses. 55 In this study, just over half of the clozapine coprescribingwas with risperidone. This suggeststhat a number of prescribers may have been augmenting a partial response to clozapine; however, it was beyond the scope of this study to examineclinicalindications for coprescribing. Some practices observed have no evidence to support coprescribing; multiple (>2) antipsychotics and combinations including a depot antipsychotic should be avoidedbecause of the risk of prolonged bone marrowsuppression.F-" This study also found that schizophrenia patients, irrespectiveof whetherthey were treated with clozapineor alternative antipsychotic(s), were prescribed an average of only 2 psychotropics,including the antipsychotic.This is possibly due to low rates of comorbid mental illness reportedin both treatment groups (20% and 25%, respectively). A slightly higher number of psychopharmacologic medications (averageof 3) were reported in a US study of schizophrenia patients in routine practice; 41% of this group had comorbidmentalillness,"
Most commonly coprescribed psychotropicsin this review were for the managementof adverse effects, 25% of the clozapinegroup compared with 19% in the non-clozapine group.Terazosin and benztropine havebeenreported to be effective in the management of clozapine-induced hypersalivation," which occurs in approximately 30%of patients," Withnon-elozapine antipsychotics, anticholinergics are recommended mostcommonly for themanagement of acute extrapyramidal symptoms. About 11 % of the clozapine group wascoprescribed a sedative-hypnotic, which was lowerthan therate forthe non-elozapine group (17%). A possible explanation is that sedation is the most commonly reported adverse effect caused by c1ozapine's pharmacologic profile (_39%).14 Clonazepam,a long-acting benzodiazepine, was the most frequently coprescribedsedative-hypnotic. This may be explainedby augmentation of clozapinepartial responders(psychoticagitation,irritability, anxiety)," rather than useas a sedative-hypnotic. Concomitant antidepressants and mood stabilizerswere prescribedfor less than 20% of both treatmentgroups, and there was no significantdifferencein the rates between groups.
UMITAnONS
The fmdings of this study representreal-world prescribing for all schizophrenia patients attending a CMHC in Aucklandand Northland. It reflects the total antipsychotic regimen that the prescriber intended the patient to take at the time of the review; however,the study did not explore adherence to or the clinical effects of treatment. The methodology employedcross-sectional data that were documentedin the outpatient clinical recordsand collected retrospectively.Therefore, the quality of the study data was dependent to a large extent on the quality of the clinical recordings made by the mentalhealthclinicians. It was beyond the scope of this study to examine whether patients were ever offered clozapine and reasons why prescribers mayor may not have recommended a clozapine trial or why patients mayor may not have agreed to such a trial.
The study findings may not be generalizable to other settings, such as elderly services or primarycare; however, the findings reflect antipsychotic prescribing by more than 50 prescribers for approximately one-third of adult outpatients with schizophrenia or schizoaffective disorderliving in New Zealand.
Conclusions
This study suggests that patients with treatment-resistant schizophrenia were able to access c1ozapine,but its use was delayed in many.It appearsthat youngerpatientswith shorter treatment histories were prescribed clozapineearlier. Accessto clozapine may have been supported by the increase in funding, publication of guidelines, and increasing clinician experience with the agent over time. In routine practice, where there were no restrictionson concomitant prescribing, low rates were found, typically consisting of the antipsychotic and another medication to treat its adverse effects.These findings have been presentedto clinicians as part of the auditcycle feedback in an effortto reinforce best-practice and increase appropriate adherence to best-practice recommendations. Further work supporting earlier clozapine initiation, especially in the community setting,is ongoing.Other initiatives to addresssome of the potential barriersto early use of clozapine includeassertive community treatment teamsto assistwith supervised medication administration and use of otherhealthcare and service providers, suchas primary care and residential rehabilitation, to assist in monitoring while treatment is initiated.
Tratamiento y Perfil de Prescripci6n de la Esquizofrenia en Nueva Zelanda AJWheeler Ann Pharmacother 2008;42:852-60.
EXTRACfO
OJUmVO: Describir el tratarniento y el perfil de utilizaci6n de la clozapina en la esquizofrenia, incluyendo la prescripci6n asociadaa otros psicofarmacos, comparando el gradode prescripci6n asociadaentre pacientesesquizotrenicos tratados0 no con ciozapinay atendidos en los centrosde salud mentalde las regionesde Aucklandy Northlandde NuevaZelanda. ME.roDO: Se realiz6una revisi6nretrospectiva de las historias clfnicas de los pacientes adultosque eran atendidos en los centrosde salud mental de octubreel 31 de 2004.Los datos recogidos para todos los pacientesa los que se les prescribi6 un antipsic6tico inclufan variables demograficas (genero,edad, etnia),diagn6stico principal DSM-IV, comorbillidad, duraci6nde la enfermedadmental,ingresos psiquiatricos. e informaci6n sobretratamientos (psicofarmacos, dosis, y via de adrninistraci6n). Alli donde se inici6tratarniento con ciozapina,despuesde la introducci6n de un subsidiogubemamental de la totalidadde la prescripci6n (febrero 1999),se aiiadieron datos adicionales como el ai'io de inicioy la historia previade utilizaci6n de antipsic6ticos. El analisisincluy6todos los pacientesexternoscon diagn6stico de esquizofrenia (incluyendo los trastomospsicoafectivos). RESULTADOS: Se prescribieron antipsic6ticos a un totalde 2796pacientes; se prescribi6 clozapinaa un 32.8%de estes, a una dosis mediade 372 mg/dia,con un promediode duraci6nde la enfermedadde 9.7 ai'ios antesde iniciar la clozapina. El59% iniciaron el tratarniento conclozapina ctespues de que fuerafmanciada por el gobiemo y presentanunamedia de utilizaci6n de 3 antipsic6ticos, antesde iniciar la clozapina. Muchos utilizaron un antipsic6tico de segundageneraci6n (91%). Los pacientes con clozapinapresentaban menorprobabilidad de utilizarotro antipsic6-tico comparadocon los que no utilizaban la ciozapina(12%vs 18%;P < 0.(01). Tantoel grupo de clozapina como el de no clozapina,tenfan un mimerototal de antipsic6ticos prescritos bajo (media= 2). Para la clozapina, el segundo medicamento fue sobretodoparala hipersalivaci6n. CONCLUSJONFS: Lospacientes externos con esquizofrenia resistente aeceden a la clozapinaen la proporci6n prevista; sin embargoel tratamiento se retras6mas de 10recomendado. Existe algunaevidenciade la mejoraen el accesoa la clozapinapara el tratarniento de la esquizofrenia resistente. posiblemente como resultadode la introducci6n de la financiaci6n del gobierno,de la difusi6nde las gufas0 por la mayorexperienciade los clfnicos, En este entomo,el mirnero de farmacos asociados a los antipsi-c6ticos paralospacientes externos conesquizofrenia fue bajo,y en el caso de la clozapina,fue habitualrnente para tratarlos efectosadversos. alaclozapine dans lescasresistants s'estameliore, possiblement en raison de la mise sur pied du programmed'acces gouvememental, de la publication de lignesdirectrices de traitement,et d'une expertise cliniqueplus grandeavec la clozapine.En milieureel,le nombrede coprescriptions de psychotropes est faibleet, pour Ie groupe recevantde la clozapine,la co-prescription servaitsurtoutacontrolerles etfets indesirables du medicament.
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